shutterstock_1650524983_sundry_photography
Sundry Photography / Shutterstock.com
23 September 2020AmericasSarah Morgan

Illumina to acquire Jeff Bezos-backed cancer testing company

Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 August 2020   Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
Big Pharma
14 May 2020   Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.
Americas
7 December 2020   Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.

More on this story

Americas
7 December 2020   Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
Americas
13 August 2020   Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
Big Pharma
14 May 2020   Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.

More on this story

Americas
7 December 2020   Pharmaceutical companies Illumina and Roche have been sued for allegedly infringing two patents covering the technology for non-invasive DNA testing by Maryland genetic testing company Ravgen.
Americas
13 August 2020   Beijing-based BGI Genomics can continue to develop its DNA sequencing technology pending an appeal in a patent dispute with Illumina, a US federal court has ruled.
Big Pharma
14 May 2020   Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.